Brokerages expect Solid Biosciences Inc. (NASDAQ:SLDB) to announce ($0.28) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Solid Biosciences’ earnings. Solid Biosciences posted earnings of ($0.52) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 46.2%. The firm is scheduled to issue its next quarterly earnings results on Thursday, May 6th.
On average, analysts expect that Solid Biosciences will report full-year earnings of ($1.11) per share for the current fiscal year, with EPS estimates ranging from ($1.46) to ($0.72). For the next year, analysts expect that the firm will post earnings of ($0.98) per share, with EPS estimates ranging from ($1.35) to ($0.61). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Solid Biosciences.
Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Sunday, March 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.03.
In other news, Director Ra Capital Management, L.P. bought 2,206,685 shares of the company’s stock in a transaction that occurred on Friday, March 19th. The stock was acquired at an average price of $5.75 per share, for a total transaction of $12,688,438.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Carl Ashley Morris sold 23,398 shares of the stock in a transaction dated Friday, March 12th. The stock was sold at an average price of $8.84, for a total transaction of $206,838.32. Following the sale, the insider now owns 287,301 shares of the company’s stock, valued at approximately $2,539,740.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,486 shares of company stock valued at $336,319. Corporate insiders own 31.20% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System increased its position in shares of Solid Biosciences by 16.5% during the 3rd quarter. California State Teachers Retirement System now owns 36,076 shares of the company’s stock worth $73,000 after purchasing an additional 5,102 shares in the last quarter. First Trust Advisors LP grew its holdings in Solid Biosciences by 25.4% during the 4th quarter. First Trust Advisors LP now owns 84,824 shares of the company’s stock worth $643,000 after acquiring an additional 17,208 shares during the last quarter. Rhumbline Advisers grew its holdings in Solid Biosciences by 23.5% during the 4th quarter. Rhumbline Advisers now owns 35,001 shares of the company’s stock worth $265,000 after acquiring an additional 6,661 shares during the last quarter. ExodusPoint Capital Management LP bought a new stake in Solid Biosciences during the 4th quarter worth about $348,000. Finally, Citigroup Inc. grew its holdings in Solid Biosciences by 62.8% during the 4th quarter. Citigroup Inc. now owns 9,465 shares of the company’s stock worth $72,000 after acquiring an additional 3,652 shares during the last quarter. Institutional investors and hedge funds own 42.73% of the company’s stock.
Shares of SLDB stock traded up $0.10 during trading hours on Thursday, reaching $4.98. 16,905 shares of the stock traded hands, compared to its average volume of 1,705,740. Solid Biosciences has a 1-year low of $1.93 and a 1-year high of $11.58. The business has a fifty day moving average price of $7.20 and a 200 day moving average price of $5.62. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $532.25 million, a PE ratio of -2.37 and a beta of 1.10.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients' muscles.
Recommended Story: How mutual funds make money
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.